Richard Stein's Insider Trades & SAST Disclosures
Richard Stein's most recent trade in BioXcel Therapeutics Inc was a trade of 34 Restricted Stock Units done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard Stein.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 1,373 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 1,339 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 229 | - | - | Restricted Stock Units | |
| LPL Financial Holdings Inc | Richard Steinmeier | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 7,836 | 29,232 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 6,971 | 31,439 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 357.36 per share. | 25 Feb 2025 | 4,764 | 24,468 (0%) | 0% | 357.4 | 1,702,463 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 373.79 per share. | 18 Feb 2025 | 3,500 | 21,396 (0%) | 0% | 373.8 | 1,308,265 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 5,064 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 21,362 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 20,800 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 372 | 20,932 (0%) | 0% | 0.4 | 133 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 205 | 21,157 (0%) | 0% | 0.4 | 74 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 27,454 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 7,175 | 20,279 (0%) | 0% | 0.5 | 3,946 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 6,560 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 5,625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 5,997 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 14 Sep 2024 | 356 | 6,204 (0%) | 0% | 0.7 | 246 | Common Stock |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 5,848 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 6,188 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 5,286 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 14 Jun 2024 | 372 | 5,476 (0%) | 0% | 1.3 | 470 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 5,834 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 14 Mar 2024 | 1,069 | 4,765 (0%) | 0% | 2.6 | 2,817 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 3,584 (0%) | 0% | - | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2024 | 12,776 | 29,690 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Steinmeier Richard | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 263.36 per share. | 25 Feb 2024 | 7,397 | 22,293 (0%) | 0% | 263.4 | 1,948,074 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2024 | 2,603 | 24,896 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 3,063 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 2,542 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 2,021 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 14 May 2023 | 5,000 | 1,500 (0%) | 0% | 27.2 | 135,864 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 6,500 (0%) | 0% | - | Common Stock | |
| Liberty Resources Acquisit... | Garry Richard Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 30,000 | 40,000 | - | - | Class B Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 14 Mar 2023 | 2,084 | 1,500 (0%) | 0% | 19.5 | 40,638 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 3,584 (0%) | 0% | - | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 12,396 | 32,737 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.30 per share. | 25 Feb 2023 | 7,379 | 25,358 (0%) | 0% | 247.3 | 1,824,827 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 1,856 | 27,214 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.95 per share. | 16 Feb 2023 | 723 | 44,939 (0%) | 0% | 37.0 | 26,715 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.66 per share. | 16 Feb 2023 | 722 | 45,662 (0%) | 0% | 36.7 | 26,469 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 11,439 | 11,439 | - | - | Stock Appreciation Rights | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 8,092 | 46,384 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.17 per share. | 12 Feb 2023 | 1,501 | 38,292 (0%) | 0% | 37.2 | 55,792 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.24 per share. | 06 Feb 2023 | 2,362 | 39,793 (0%) | 0% | 37.2 | 87,961 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.79 per share. | 07 Sep 2022 | 3,737 | 20,341 (0%) | 0% | 223.8 | 836,303 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.53 per share. | 04 Aug 2022 | 7,355 | 31,433 (0%) | 0% | 77.5 | 570,233 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2022 | 7,355 | 0 | - | - | Option to purchase Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Sale of securities on an exchange or to another person at price $ 216.64 per share. | 04 Aug 2022 | 7,355 | 24,078 (0%) | 0% | 216.6 | 1,593,387 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.00 per share. | 17 May 2022 | 409 | 42,155 (0%) | 0% | 37 | 15,133 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Senior VP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 500,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 33,350 | 33,350 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 6,534 | 25,700 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 182.73 per share. | 25 Feb 2022 | 4,234 | 21,466 (0%) | 0% | 182.7 | 773,679 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 2,612 | 24,078 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 10,942 | 10,942 | - | - | Stock Appreciation Rights | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 7,304 | 43,286 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.19 per share. | 16 Feb 2022 | 722 | 42,564 (0%) | 0% | 48.2 | 34,793 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.54 per share. | 11 Feb 2022 | 1,501 | 35,982 (0%) | 0% | 48.5 | 72,859 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.34 per share. | 04 Feb 2022 | 2,315 | 37,483 (0%) | 0% | 47.3 | 109,592 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.69 per share. | 07 Sep 2021 | 3,736 | 19,166 (0%) | 0% | 147.7 | 551,770 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.90 per share. | 17 May 2021 | 410 | 39,798 (0%) | 0% | 42.9 | 17,589 | Common Stock |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Fifth Third Bancorp | Richard Stein | EVP | Sale of securities on an exchange or to another person at price $ 39.10 per share. | 26 Apr 2021 | 18,472 | 40,208 (0%) | 0% | 39.1 | 722,255 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Sale of securities on an exchange or to another person at price $ 136.67 per share. | 08 Mar 2021 | 1,406 | 22,902 (0%) | 0% | 136.7 | 192,158 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 4,259 | 24,308 (0%) | 0% | 0 | Common Stock | |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.10 per share. | 25 Feb 2021 | 788 | 20,049 (0%) | 0% | 132.1 | 104,095 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 13,393 | 13,393 | - | - | Stock Appreciation Right | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 8,140 | 53,787 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 7,307 | 58,680 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.93 per share. | 17 Feb 2021 | 2,414 | 51,373 (0%) | 0% | 28.9 | 69,837 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.51 per share. | 12 Feb 2021 | 1,501 | 45,647 (0%) | 0% | 32.5 | 48,798 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.10 per share. | 05 Feb 2021 | 2,233 | 47,148 (0%) | 0% | 32.1 | 71,679 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.55 per share. | 01 Feb 2021 | 3,750 | 5,250 (0%) | 0% | 5.6 | 20,813 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 3,750 | 80,148 | - | - | Stock Option | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.15 per share. | 01 Feb 2021 | 3,750 | 1,500 (0%) | 0% | 48.2 | 180,563 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.93 per share. | 29 Jan 2021 | 843 | 49,381 (0%) | 0% | 28.9 | 24,388 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Sale of securities on an exchange or to another person at price $ 25.77 per share. | 11 Nov 2020 | 81 | 0 (0%) | 0% | 25.8 | 2,087 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Sale of securities on an exchange or to another person at price $ 25.74 per share. | 11 Nov 2020 | 19 | 0 (0%) | 0% | 25.7 | 489 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 09 Nov 2020 | 3,984 | 20,837 (0%) | 0% | 86 | 342,624 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.76 per share. | 07 Sep 2020 | 3,552 | 24,821 (0%) | 0% | 83.8 | 297,516 | Common Stock |
| LPL Financial Holdings Inc | Richard Steinmeier | Managing Director | Sale of securities on an exchange or to another person at price $ 86.02 per share. | 09 Jun 2020 | 5,418 | 28,373 (0%) | 0% | 86.0 | 466,056 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 55,000 | 55,000 | - | - | Employee Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Richard I. Steinhart | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 45,000 | 45,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges